Prosecution Insights
Last updated: September 17, 2026
Application No. 18/835,391

ORAL CARE COMPOSITION COMPRISING POROUS SILICA PARTICLES

Non-Final OA §102
Filed
Aug 02, 2024
Priority
Feb 04, 2022 — GB 2201484.9 +1 more
Examiner
TRAN, SUSAN T
Art Unit
Tech Center
Assignee
Sigrid Therapeutics AB
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
650 granted / 1036 resolved
+2.7% vs TC avg
Strong +35% interview lift
Without
With
+34.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
24 currently pending
Career history
1073
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
41.0%
+1.0% vs TC avg
§102
20.7%
-19.3% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1036 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-12 and 15-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Canham US 20090214451 A1. Canham teaches an oral hygiene composition comprising silicon abrasive particulates having a mean particle size in the range between 1µm to 100 µm. See Abstract and paragraphs 0021-0022. Silicon particulates include mesoporous silica having average pore size between 2 nm to 50 nm. See paragraph 0027. Typically, the porous silicon abrasive agent according to the present invention may possess a BET surface area in the range of 100 to 700 m2/g, for example 200 to 500 m2/g. See paragraph 0028. Dentifrice Composition "Dentifrice composition" as used herein, includes a toothpaste, tooth powder, prophylaxis paste, lozenge, dragee, bon-bon, gum or oral gel. The oral gel may be of the type suitable for use in multi-stage whitening systems. The dentifrice composition, in which the particulate silicon abrasive is used according to the present invention, will comprise constituents well known to one of ordinary skill; these may broadly be characterised as active and inactive agents. Active agents include anticaries agents such as fluoride, antibacterial agents, desensitising agents, antitartar agents (or anticalculus agents) and whitening agents. Inactive ingredients are generally taken to include water (to enable the formation of a water phase), detergents, surfactants or foaming agents, thickening or gelling agents, binding agents, efficacy enhancing agents, humectants to retain moisture, flavouring, sweetening and colouring agents, preservatives and, optionally in addition to the silicon abrasive of the present invention, further abrasives for cleaning and polishing. See paragraph 0039. Claims 31 and 33 disclose a method for reducing stain and/or plaque and/or gingivitis comprising the application of a safe and effective amount of a dentifrice composition. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN T TRAN whose telephone number is (571)272-0606. The examiner can normally be reached Monday-Friday, 8:30 am-5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ROBERT A. WAX can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN T TRAN/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Aug 02, 2024
Application Filed
Aug 11, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734131
LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS
2y 10m to grant Granted Sep 15, 2026
Patent 12721803
COMPOSITION WITH NONSILICONE ELASTOMER AND PASTY FATTY SUBSTANCE
3y 2m to grant Granted Sep 01, 2026
Patent 12714666
ORAL DRUG DELIVERY DEVICE WITH EXPANDING ARMS
3y 5m to grant Granted Aug 25, 2026
Patent 12708617
AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF
2y 11m to grant Granted Aug 18, 2026
Patent 12691082
ORAL ADMINISTRATION OF KETAMINE
4y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
98%
With Interview (+34.9%)
3y 1m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1036 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month